JP2007532486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532486A5 JP2007532486A5 JP2007504145A JP2007504145A JP2007532486A5 JP 2007532486 A5 JP2007532486 A5 JP 2007532486A5 JP 2007504145 A JP2007504145 A JP 2007504145A JP 2007504145 A JP2007504145 A JP 2007504145A JP 2007532486 A5 JP2007532486 A5 JP 2007532486A5
- Authority
- JP
- Japan
- Prior art keywords
- tfpi
- composition
- analog
- administration
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 58
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 53
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 53
- 239000003146 anticoagulant agent Substances 0.000 claims 7
- 229940127219 anticoagulant drug Drugs 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 6
- 206010035664 Pneumonia Diseases 0.000 claims 6
- 229930182817 methionine Natural products 0.000 claims 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 6
- 239000001509 sodium citrate Substances 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 229930064664 L-arginine Natural products 0.000 claims 4
- 235000014852 L-arginine Nutrition 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229960003589 arginine hydrochloride Drugs 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 229940124790 IL-6 inhibitor Drugs 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 101710190786 PI protein Proteins 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 claims 1
- 108010000499 Thromboplastin Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- -1 antibodies Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000004074 complement inhibitor Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000014508 negative regulation of coagulation Effects 0.000 claims 1
- 208000026425 severe pneumonia Diseases 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55468104P | 2004-03-17 | 2004-03-17 | |
| PCT/US2005/009097 WO2005110059A2 (en) | 2004-03-17 | 2005-03-17 | Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532486A JP2007532486A (ja) | 2007-11-15 |
| JP2007532486A5 true JP2007532486A5 (enExample) | 2008-05-29 |
Family
ID=35394617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504145A Pending JP2007532486A (ja) | 2004-03-17 | 2005-03-17 | 組織因子経路インヒビターの投与による重度の市中肺炎の処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080286279A1 (enExample) |
| EP (1) | EP1729791A2 (enExample) |
| JP (1) | JP2007532486A (enExample) |
| KR (1) | KR20070007336A (enExample) |
| CN (1) | CN101426520A (enExample) |
| AU (1) | AU2005244249A1 (enExample) |
| BR (1) | BRPI0508992A (enExample) |
| CA (1) | CA2560103A1 (enExample) |
| IL (1) | IL178115A0 (enExample) |
| MX (1) | MXPA06010587A (enExample) |
| NO (1) | NO20064674L (enExample) |
| RU (1) | RU2006136267A (enExample) |
| SG (1) | SG150552A1 (enExample) |
| TN (1) | TNSN06295A1 (enExample) |
| WO (1) | WO2005110059A2 (enExample) |
| ZA (1) | ZA200608413B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0916578D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| CN112587522B (zh) * | 2020-12-03 | 2022-11-25 | 中国海洋大学 | 替加色罗在制备用于预防或治疗冠状病毒感染的药物中的应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| JPS5896026A (ja) * | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3219248A1 (de) * | 1982-05-21 | 1983-11-24 | Solco Basel AG, Birsfelden | Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut |
| EP0098110B1 (en) * | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4511502A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4711845A (en) * | 1984-08-31 | 1987-12-08 | Cetus Corporation | Portable temperature-sensitive control cassette |
| US4530787A (en) * | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US4847201A (en) * | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4748234A (en) * | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JPS6345230A (ja) * | 1986-04-01 | 1988-02-26 | Central Glass Co Ltd | ブロモベンゾトリフルオリドの製造方法 |
| US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
| US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
| US5212091A (en) * | 1992-03-02 | 1993-05-18 | Monsanto Company | Method of producing tissue factor pathway inhibitor |
| US5276015A (en) * | 1992-03-18 | 1994-01-04 | Washington University | Method of inhibiting microvascular thrombosis |
| USRE36476E (en) * | 1992-03-18 | 1999-12-28 | Washington University | Method of inhibiting microvascular thrombosis |
| US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| US5589359A (en) * | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| JP3571378B2 (ja) * | 1994-09-30 | 2004-09-29 | 扶桑薬品工業株式会社 | 感染症診断用プローブ |
| US5914316A (en) * | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
| US5569644A (en) * | 1995-05-18 | 1996-10-29 | The Lubrizol Corporation | Additive combinations for lubricants and functional fluids |
| US5612363A (en) * | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
| US6242414B1 (en) * | 1995-06-07 | 2001-06-05 | Chiron Corporation | Regulation of cytokine synthesis and release |
| US5888968A (en) * | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
| DK1602667T3 (da) * | 1995-06-07 | 2007-07-23 | Novartis Vaccines & Diagnostic | Vandig formulering omfattende TFPI og solubiliseringsmidler |
| US5885781A (en) * | 1995-06-07 | 1999-03-23 | Chiron Corporation | Regulation of cytokine synthesis and release |
| US5902582A (en) * | 1995-09-05 | 1999-05-11 | Chiron Corporation | Use of TFPI inhibitor for treatment of cancer |
| US6011136A (en) * | 1995-11-21 | 2000-01-04 | Novartis Ag | Cyclopeptolides |
| US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
| KR100442758B1 (ko) * | 1996-03-25 | 2004-10-06 | 사이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 조직인자응고계억제제함유혈관신생저해제 |
| US5977057A (en) * | 1996-05-08 | 1999-11-02 | The University Of Vermont And State Agricultural College | Thrombosis prophylaxis for factor VLEIDEN carriers |
| US5981471A (en) * | 1997-02-06 | 1999-11-09 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
| AR015598A1 (es) * | 1997-04-28 | 2001-05-16 | Lilly Co Eli | FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE. |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| US6824997B1 (en) * | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
| BR9914735A (pt) * | 1998-10-22 | 2001-07-03 | Lilly Co Eli | Processo para tratamento de sépsia |
| DE69906568T2 (de) * | 1998-11-20 | 2004-02-12 | Eli Lilly And Co., Indianapolis | Behandlung von hämorrhagischem virusfieber mit protein c |
| WO2000077246A2 (en) * | 1999-06-14 | 2000-12-21 | Novo Nordisk A/S | A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS |
| US6294648B1 (en) * | 1999-07-20 | 2001-09-25 | Bayer Corporation | Protein having proteinase inhibitor activity |
| US6180607B1 (en) * | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
| CN1245216C (zh) * | 1999-10-04 | 2006-03-15 | 希龙公司 | 稳定化的含多肽的液体药物组合物 |
| JP2003521938A (ja) * | 2000-02-11 | 2003-07-22 | イーライ・リリー・アンド・カンパニー | プロテインc誘導体 |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US7015194B2 (en) * | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| DE60217835D1 (en) * | 2001-02-28 | 2007-03-15 | John H Griffin | Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c |
| EP1383885A4 (en) * | 2001-04-04 | 2005-11-30 | American Diagnostica Inc | METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF |
| DE10132307A1 (de) * | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
| EA200400548A1 (ru) * | 2001-10-15 | 2005-06-30 | Чирон Корпорейшн | Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi) |
| US20020198138A1 (en) * | 2002-06-07 | 2002-12-26 | Macias William Louis | Combination therapy for the treatment of inflammatory and respiratory diseases |
-
2005
- 2005-03-17 EP EP05777406A patent/EP1729791A2/en not_active Withdrawn
- 2005-03-17 SG SG200901403-6A patent/SG150552A1/en unknown
- 2005-03-17 AU AU2005244249A patent/AU2005244249A1/en not_active Abandoned
- 2005-03-17 CN CNA2005800144064A patent/CN101426520A/zh active Pending
- 2005-03-17 BR BRPI0508992-1A patent/BRPI0508992A/pt not_active IP Right Cessation
- 2005-03-17 WO PCT/US2005/009097 patent/WO2005110059A2/en not_active Ceased
- 2005-03-17 MX MXPA06010587A patent/MXPA06010587A/es not_active Application Discontinuation
- 2005-03-17 CA CA002560103A patent/CA2560103A1/en not_active Abandoned
- 2005-03-17 JP JP2007504145A patent/JP2007532486A/ja active Pending
- 2005-03-17 KR KR1020067021122A patent/KR20070007336A/ko not_active Withdrawn
- 2005-03-17 RU RU2006136267/14A patent/RU2006136267A/ru not_active Application Discontinuation
- 2005-03-17 US US10/593,135 patent/US20080286279A1/en not_active Abandoned
-
2006
- 2006-09-14 IL IL178115A patent/IL178115A0/en unknown
- 2006-09-15 TN TNP2006000295A patent/TNSN06295A1/en unknown
- 2006-10-09 ZA ZA200608413A patent/ZA200608413B/en unknown
- 2006-10-16 NO NO20064674A patent/NO20064674L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506345A5 (enExample) | ||
| Van Miert | Pro‐inflammatory cytokines in a ruminant model: Pathophysiological, pharmacological, and therapeutic aspects | |
| Waage et al. | Current understanding of the pathogenesis of gram-negative shock | |
| JP2007515469A5 (enExample) | ||
| O'Brien et al. | Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products | |
| US20110165121A1 (en) | Use of pegylated type iii interferons for the treatment of hepatitis c | |
| US20220363750A1 (en) | Arthritis treatment | |
| JP2002544174A5 (enExample) | ||
| JP2005515214A5 (enExample) | ||
| RU2010142309A (ru) | Способы лечения псориаза | |
| FI4267105T3 (fi) | Vasta-ainekoostumuksia ja niiden käyttömenetelmiä | |
| RU2577299C2 (ru) | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний | |
| JP6485970B2 (ja) | 自己免疫疾患の治療のための併用療法 | |
| US20230212278A1 (en) | Pharmaceutical composition of anti-il-17a antibodies and use thereof | |
| US5660826A (en) | Therapeutic sepsis treatment using antagonists to PTHrP | |
| US5730976A (en) | Method for treating macrophage pathogen infections by TGF-B antagonists | |
| Mittelman et al. | A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion | |
| JP2023522196A (ja) | 化膿性汗腺炎の治療 | |
| JP2020531523A5 (enExample) | ||
| JP2007532486A5 (enExample) | ||
| JPWO2021123902A5 (enExample) | ||
| JP2004538275A5 (enExample) | ||
| JP2013542206A (ja) | C型肝炎ウイルス感染症の新規治療 | |
| JP2022523530A (ja) | 化膿性汗腺炎の治療のための抗IL-α抗体 | |
| DK2694090T3 (en) | PHARMACEUTICALS CONTAINING RECOMBINANT MISTELTE LECTINES FOR TREATMENT OF THE ORAL MELANOME |